December 23, 2008
Teva Pharmaceutical Industries Ltd. completes its $8.9 billion acquisition of Barr Pharmaceuticals Inc., creating a combined company with a significant presence in over 60 countries.
On December 23, it was announced that Willkie client Teva Pharmaceutical Industries Ltd. completed its $8.9 billion acquisition of Barr Pharmaceuticals Inc. The transaction, which was announced on July 18, 2008, creates a combined company with a significant presence in over 60 countries and approximately $13.6 billion in revenues on a pro-forma basis for the twelve months ended September 30, 2008. Israel-based Teva is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. Willkie represented Teva in its acquisitions of CoGenesys Inc. and Bentley Pharmaceuticals Inc. earlier this year, as well as in numerous previous transactions, including its multibillion dollar acquisitions of Ivax Corporation and Sicor Inc. Barr, now a wholly owned subsidiary of Teva, is a global specialty pharmaceutical company and the world's fourth largest generic drug company. The transaction was handled by partners Peter Jakes, Jeffrey Hochman, David Rubinsky, Christopher Peters, William Rooney, Jochen Winter, Jacques-Phillippe Gunther and David Tayar; national partner Stefan Joergens; special counsel David Park and Jonathan Konoff; and associates Mark Getachew, Manuel Miranda, Daniel Backer, Jordan Messinger, Katie Calabrese, Rebecca Gutner, Curtis Hogan, James Crowe, Jeffrey Korn, Melanie Butcher, Theodore Neos, Amy Fitzpatrick, Christopher Williamson, Kristin McNamara, and Alejandro Rosenberg.
